Fibromyalgia - 5EU Drug Forecast and Market Analysis to 2023
Fibromyalgia Market 5EU Drug Forecast and Market Analysis to 2023 "The Report Fibromyalgia 5EU Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. MarketResearchReports.biz" The fibromyalgia market is relatively new and not yet established. Three drugs currently dominate the sales across the 7MM and form the core treatment options; Lyrica, Cymbalta and Savella are all approved in the US while only the former is approved in Japan. Since these drugs are also available in the 5EU for other indications, they are prescribed as offlabel therapies. A handful of other genericized products also provide offlabel usage including antidepressants, antiepileptics, opioids and muscle relaxants. Although Lyrica, Cymbalta and Savella can provide an effective treatment regimen, there are ample opportunities for the development of alternative treatment choices which can expand the medications available to patients, providing improvement in efficacy, safety and compliance. By 2023, there will be four new entrants to the market (Lyrica CR, TNX102 SL, DS5565 and TD9855). These new products will help to drive market growth and offset some of the patent expiries of the leading brands during the forecast period. Despite these advancements in the treatment landscape, fibromyalgia therapeutic sales growth are expected to be minimal. GlobalData estimates that the fibromyalgia market across the 5EU reached sales of approximately $149.7m in 2013. The EU market is expected to grow at a slower rate compared with the US, owing to a lack of approved brands and the fact that only one pipeline product is expected to enter the fibromyalgia market during the forecast period. Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/825701 Scope Overview of Fibromyalgia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in 5EU from 20132023. Analysis of the impact of key events as well the drivers and restraints affecting 5EU Fibromyalgia market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust
- Page 2 and 3: eturn Stay ahead of the competit
<strong>Fibromyalgia</strong> <strong>Market</strong> <strong>5EU</strong> <strong>Drug</strong> <strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong><br />
"The Report <strong>Fibromyalgia</strong> <strong>5EU</strong> <strong>Drug</strong> <strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong> provides<br />
information on pricing, market analysis, shares, forecast, <strong>and</strong> company profiles for<br />
key industry participants. <strong>Market</strong>ResearchReports.biz"<br />
The fibromyalgia market is relatively new <strong>and</strong> not yet established. Three drugs currently<br />
dominate the sales across the 7MM <strong>and</strong> form the core treatment options; Lyrica, Cymbalta<br />
<strong>and</strong> Savella are all approved in the US while only the former is approved in Japan. Since<br />
these drugs are also available in the <strong>5EU</strong> for other indications, they are prescribed as offlabel<br />
therapies. A h<strong>and</strong>ful of other genericized products also provide offlabel usage<br />
including antidepressants, antiepileptics, opioids <strong>and</strong> muscle relaxants. Although Lyrica,<br />
Cymbalta <strong>and</strong> Savella can provide an effective treatment regimen, there are ample<br />
opportunities for the development of alternative treatment choices which can exp<strong>and</strong> the<br />
medications available <strong>to</strong> patients, providing improvement in efficacy, safety <strong>and</strong><br />
compliance. By <strong>2023</strong>, there will be four new entrants <strong>to</strong> the market (Lyrica CR, TNX102<br />
SL, DS5565 <strong>and</strong> TD9855). These new products will help <strong>to</strong> drive market growth <strong>and</strong><br />
offset some of the patent expiries of the leading br<strong>and</strong>s during the forecast period. Despite<br />
these advancements in the treatment l<strong>and</strong>scape, fibromyalgia therapeutic sales growth are<br />
expected <strong>to</strong> be minimal.<br />
GlobalData estimates that the fibromyalgia market across the <strong>5EU</strong> reached sales of<br />
approximately $149.7m in 2013. The EU market is expected <strong>to</strong> grow at a slower rate<br />
compared with the US, owing <strong>to</strong> a lack of approved br<strong>and</strong>s <strong>and</strong> the fact that only one<br />
pipeline product is expected <strong>to</strong> enter the fibromyalgia market during the forecast period.<br />
Download Sample copy of this Report at :<br />
http://www.marketresearchreports.biz/sample/sample/825701<br />
Scope<br />
Overview of <strong>Fibromyalgia</strong> including epidemiology, etiology, symp<strong>to</strong>ms, diagnosis,<br />
pathology <strong>and</strong> treatment guidelines as well as an overview on the competitive l<strong>and</strong>scape.<br />
Detailed information on the key drugs in <strong>5EU</strong> including product description, safety <strong>and</strong><br />
efficacy profiles as well as a SWOT analysis.<br />
Sales forecast for the <strong>to</strong>p drugs in <strong>5EU</strong> from 2013<strong>2023</strong>.<br />
<strong>Analysis</strong> of the impact of key events as well the drivers <strong>and</strong> restraints affecting <strong>5EU</strong><br />
<strong>Fibromyalgia</strong> market.<br />
Reasons <strong>to</strong> buy<br />
Underst<strong>and</strong> <strong>and</strong> capitalize by identifying products that are most likely <strong>to</strong> ensure a robust
eturn<br />
Stay ahead of the competition by underst<strong>and</strong>ing the changing competitive l<strong>and</strong>scape for<br />
<strong>Fibromyalgia</strong>.<br />
Effectively plan your M&A <strong>and</strong> partnership strategies by identifying drugs with the most<br />
promising sales potential<br />
Make more informed business decisions from insightful <strong>and</strong> indepth analysis of drug<br />
performance<br />
Obtain sales forecast for drugs from 2013<strong>2023</strong> in <strong>5EU</strong>.<br />
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreportsbiz<br />
Table of Contents<br />
1 Table of Contents<br />
1 Table of Contents 2<br />
1.1 List of Tables 5<br />
1.2 List of Figures 7<br />
2 Introduction 8<br />
2.1 Catalyst 8<br />
2.2 Related Reports 8<br />
2.3 Upcoming Related Reports 9<br />
3 Disease Overview 10<br />
3.1 Etiology <strong>and</strong> Pathophysiology 10<br />
3.1.1 Etiology 10<br />
3.1.2 Pathophysiology 12<br />
3.2 Classification 16<br />
3.3 Symp<strong>to</strong>ms 16<br />
3.4 Quality of Life 17<br />
4 Disease Management 18<br />
4.1 Diagnosis <strong>and</strong> Treatment Overview 18<br />
4.1.1 Diagnosis 18<br />
4.1.2 Treatment Guidelines <strong>and</strong> Leading Prescribed <strong>Drug</strong>s 20<br />
4.1.3 Clinical Practice 22<br />
4.2 France 24<br />
4.3 Germany 25<br />
4.4 Italy 27<br />
4.5 Spain 29<br />
4.6 UK 31<br />
5 Competitive Assessment 34<br />
5.1 Overview 34<br />
5.2 Product Profiles 35<br />
5.2.1 Cymbalta (duloxetine) 35<br />
5.2.2 Savella (milnacipran) 39<br />
5.2.3 Lyrica (pregabalin) 44<br />
5.2.4 Neurontin (gabapentin) 49<br />
About us<br />
<strong>Market</strong>ResearchReports.biz is the most comprehensive collection of market research
eports. <strong>Market</strong>ResearchReports.Biz services are specially designed <strong>to</strong> save time <strong>and</strong> money<br />
for our clients. We are a one s<strong>to</strong>p solution for all your research needs, our main offerings<br />
are syndicated research reports, cus<strong>to</strong>m research, subscription access <strong>and</strong> consulting<br />
services. We serve all sizes <strong>and</strong> types of companies spanning across various industries.<br />
Contact<br />
State Tower<br />
90 Sate Street, Suite 700<br />
Albany, NY 12207<br />
Tel: +15186212074<br />
Website: http://www.marketresearchreports.biz/<br />
E: sales@marketresearchreports.biz
Change language